Video Series Tackles Prostate Cancer and ADT Use in Doctor-Patient Format

Video Series Tackles Prostate Cancer and ADT Use in Doctor-Patient Format
CURE Media Group has introduced a video discussion series on topics of concern to prostate cancer patients, including cardiovascular risk management and androgen deprivation therapy (ADT). Called "ADT in Prostate Cancer: Managing Cardiovascular Risk," the nine-episode series features Andy Rochester, a prostate cancer survivor, discussing his experiences with Susan F. Slovin, an oncologist at Memorial Sloan Kettering Cancer Center and a member of his care team. ”We are thrilled to launch this video series,” Michael J. Hennessy Jr., president of MJH Associates, the parent company of CURE Media Group, said in a press release. “It is insightful to watch Rochester share his personal experience going through prostate cancer with Slovin and the audience.” ADT, a form of hormone therapy, is a treatment option for prostate cancer patients. It reduces the levels of male hormones — androgens — to prevent them from promoting cancer cell growth. It is widely given people with advanced prostate cancer. Some studies suggest ADT may increase a person's risk of cardiovascular disease, but evidence
Subscribe or to access all post and page content.